MINNEAPOLIS, MINNESOTA--(Marketwired - April 17, 2014) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
DiaMedica Inc. (TSX VENTURE:DMA), announces that it has made application to the TSX Venture Exchange to amend 1,055,600 warrants (the "Warrants") of DiaMedica by extending the expiry date from May 8, 2014 to February 8, 2015.
The Warrants formed part of an early exercise program completed in May, 2012 pursuant to a warrant indenture dated May 8, 2012 as amended and restated on July 8, 2013. No Warrants have been exercised to date.
The above described amendment is subject to approval of the TSX Venture Exchange.
DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica's lead clinical stage compound, DM199, is a recombinant human protein known as rhKLK1 that represents a novel approach to treating diabetes and associated complications. DiaMedica is also developing a monoclonal antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical development.
DiaMedica is listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this News Release.